Translate this page into:
Alpha Therapy with 225Actinium Labeled Prostate Specific Membrane Antigen: Reporting New Photopeak of 78 Kilo-electron Volts for Better Image Statistics
Address for correspondence: Dr. Rashid Rasheed, Department of Chemistry, Government College University, Kotwali Road, Faisalabad 38000, Pakistan. E-mail: dr.nmd.paec@gmail.com
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
This article was originally published by Medknow Publications & Media Pvt Ltd and was migrated to Scientific Scholar after the change of Publisher.
Sir,
Recent work has shown that Alpha-emitting radioisotope Actinium-225 (225Ac) appears more effective than other radionuclides due to better half-life and targeted radiolabeling.[12] Limited imaging data are available on the posttherapy imaging using 225Ac labeled prostate-specific membrane antigen (225Ac-PSMA) radioligand therapy in metastatic castration-resistant prostate cancer.[3] The count rate or imaging statistics can be used to enhance the image quality in posttherapy 225Ac images to have a better image contrast for assessment of tracer localization in the target/metastatic lesions. Moreover, high image count rate is also helpful in dosimetry calculations and assessment of in-vivo biodistribution. Current literature suggests clinical imaging using two photopeaks 440 kilo-electron volts (KeV) (26.5% of 213Bi decays to give 440 KeV) and 218 KeV during 225Ac-PSMA therapy.[4] However, during our initial study of 225Ac gamma-ray spectrum, it was noted that 225Ac has a third notable photopeak of 78 KeV [Figure 1], which shows higher share of photon abundance then the rest of the photopeaks, that is, 440 KeV and 218 KeV. The effective imaging potential of each peak was studied with hot-rod phantom [Figure 2] using medium energy collimator as per recommendations for 225Ac quality control. The results showed that 78 KeV peaks have significant count statistics for imaging [Figure 2b] when compared to prior recommended photopeaks as shown in Figure 2c. The images acquired with addition of 78 kev photo peak has better count statistics then the images taken with only two photo peaks of 440 KeV and 218 KeV. The technetium-99m phantom images were also acquired, as for exemplary image of high counts for visual comparison with 225Ac images as shown in Figure 2a.


Posttherapy images are a potential source of quality control to confirm the localization of 225Ac-PSMA-617 in the target metastatic sites; therefore, posttherapy imaging has vital place in the management of cancer patients, especially to differentiate posttherapy flare from other possible systemic adverse effects after radionuclide therapy and to calculate organ dosimetry wherever required. It is, therefore, suggested that photopeak of 78 KeV may be included in the imaging of 225Ac-PSMA-617 therapy to get better image quality and to perform better statistical analysis.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
References
- Actinium-225 in targeted alpha-particle therapeutic applications. Curr Radiopharm. 2011;4:306-20.
- [Google Scholar]
- Therapeutic radionuclides: Biophysical and radiobiologic principles. Semin Nucl Med. 2008;38:358-66.
- [Google Scholar]
- Targeted alpha therapy: Evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer. Australas Radiol. 1999;43:480-6.
- [Google Scholar]
- Molecular targeted α-particle therapy for oncologic applications. AJR Am J Roentgenol. 2014;203:253-60.
- [Google Scholar]